Antibacterial Diamide Compounds Inhibiting Autolysin Enzymes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibiotics face challenges due to bacterial resistance mechanisms, particularly the natural recycling of peptidoglycan by autolysins, which complicates the development of effective inhibitors, and existing compounds have shown limited bacteriostatic or bactericidal activity.
Innovation Solution
Development of novel compounds, such as those of formula I, which inhibit N-acetylglucosaminidases, specifically targeting bacterial autolysins to disrupt peptidoglycan recycling, thereby addressing resistance issues and enhancing antibacterial efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing antibiotics target peptidoglycan synthesis, then bacterial cell wall formation is inhibited, but bacteria develop resistance through autolysin-mediated peptidoglycan recycling
Solution Approach 1:
The patent extracts and targets the specific enzymatic function of autolysins (N-acetylglucosaminidase activity) that mediates peptidoglycan recycling. By designing inhibitors that specifically bind to and block this enzymatic activity, the patent removes the bacteria's ability to recycle cell wall material, thereby preventing resistance development while maintaining antibacterial efficacy.
Solution Approach 2:
The patent changes the molecular parameters of the inhibitors to optimize their binding affinity and specificity for autolysin enzymes. Through structural modification and optimization of chemical properties, the inhibitors achieve potent and selective inhibition of bacterial autolysins, enhancing antibacterial activity while minimizing resistance.
2Quantity of substance
If efflux pumps are present in bacterial membrane, then intracellular antibiotics are pumped out, but therapeutic concentrations cannot be achieved
Solution Approach 1:
The patent employs compounds that act as intermediaries to overcome efflux pump activity. These compounds are designed with molecular features that prevent recognition by efflux pumps or that can disrupt pump function, thereby serving as mediators that allow sufficient antibiotic accumulation inside bacterial cells to achieve therapeutic concentrations.
3Reliability
If antibiotics are designed to inhibit cell wall synthesis, then bacterial growth is inhibited, but the drugs may damage host cells
Solution Approach 1:
The patent applies local quality by designing inhibitors with high specificity for bacterial autolysin enzymes. The molecular structure of these inhibitors contains specific functional groups and spatial arrangements that match the active site of bacterial N-acetylglucosaminidases, allowing selective binding and inhibition of bacterial targets while leaving human enzymes unaffected, thus preventing host cell damage.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds demonstrate antibacterial activity against various Gram-positive and Gram-negative bacteria, including B. subtilis, S. pneumoniae, C. difficile, and S. aureus, with potential for reduced resistance build-up, offering a new approach to treating bacterial infections.
Implementation Method 1
Development of novel compounds, such as those of formula I, which inhibit N-acetylglucosaminidases, specifically targeting bacterial autolysins to disrupt peptidoglycan recycling
Data Source
AI summary
The invention provides novel antibacterial diamide compounds, pharmaceutical compositions comprising the compounds and methods for treating or preventing an infection in a subject using the compounds.